Amgen is planning to push its olpasiran candidate for reducing lipoprotein(a) into phase 3 as quickly as possible as it tries to catch up with rival programmes at Novartis.

MISSIONSQUARE GROWTH FUND CLASS R9- Performance charts including intraday, historical charts and prices and keydata.

MISSIONSQUARE GROWTH & INCOME FUND CLASS R9- Performance charts including intraday, historical charts and prices and keydata.